nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—ORM1—bile—bile duct cancer	0.0626	0.357	CbGeAlD
Vemurafenib—Etoricoxib—PTGS2—bile duct cancer	0.0177	1	CrCbGaD
Vemurafenib—ORM1—gall bladder—bile duct cancer	0.0174	0.0991	CbGeAlD
Vemurafenib—ALB—gall bladder—bile duct cancer	0.0152	0.0869	CbGeAlD
Vemurafenib—RAF1—pancreas—bile duct cancer	0.0116	0.0661	CbGeAlD
Vemurafenib—BRAF—liver—bile duct cancer	0.0111	0.0632	CbGeAlD
Vemurafenib—BRAF—lymph node—bile duct cancer	0.00849	0.0484	CbGeAlD
Vemurafenib—RAF1—liver—bile duct cancer	0.00738	0.0421	CbGeAlD
Vemurafenib—RAF1—lymph node—bile duct cancer	0.00566	0.0323	CbGeAlD
Vemurafenib—ORM1—liver—bile duct cancer	0.00509	0.0291	CbGeAlD
Vemurafenib—ALB—liver—bile duct cancer	0.00447	0.0255	CbGeAlD
Vemurafenib—ORM1—lymph node—bile duct cancer	0.00391	0.0223	CbGeAlD
Vemurafenib—ABCC1—liver—bile duct cancer	0.00369	0.021	CbGeAlD
Vemurafenib—ALB—lymph node—bile duct cancer	0.00343	0.0195	CbGeAlD
Vemurafenib—ABCG2—liver—bile duct cancer	0.00305	0.0174	CbGeAlD
Vemurafenib—CYP1A2—liver—bile duct cancer	0.00294	0.0168	CbGeAlD
Vemurafenib—ABCC1—lymph node—bile duct cancer	0.00283	0.0161	CbGeAlD
Vemurafenib—ABCG2—lymph node—bile duct cancer	0.00234	0.0133	CbGeAlD
Vemurafenib—CYP3A4—liver—bile duct cancer	0.00213	0.0121	CbGeAlD
Vemurafenib—CYP2D6—liver—bile duct cancer	0.00209	0.0119	CbGeAlD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—bile duct cancer	0.000495	0.000613	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—EGFR—bile duct cancer	0.000494	0.000612	CbGpPWpGaD
Vemurafenib—ALB—Platelet degranulation—TGFB1—bile duct cancer	0.000491	0.000608	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—IDH2—bile duct cancer	0.000489	0.000606	CbGpPWpGaD
Vemurafenib—BRAF—NGF signalling via TRKA from the plasma membrane—HRAS—bile duct cancer	0.000487	0.000603	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—KRAS—bile duct cancer	0.000482	0.000598	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—MMP2—bile duct cancer	0.000481	0.000595	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—KRAS—bile duct cancer	0.00048	0.000595	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—KRAS—bile duct cancer	0.00048	0.000595	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—KRAS—bile duct cancer	0.000478	0.000592	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—KRAS—bile duct cancer	0.000475	0.000589	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—EGFR—bile duct cancer	0.000473	0.000587	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—EGFR—bile duct cancer	0.000473	0.000587	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—EGFR—bile duct cancer	0.000473	0.000587	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—TP53—bile duct cancer	0.000471	0.000584	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—EGFR—bile duct cancer	0.000469	0.000581	CbGpPWpGaD
Vemurafenib—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—bile duct cancer	0.000467	0.000579	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—KRAS—bile duct cancer	0.000466	0.000578	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—EGFR—bile duct cancer	0.000466	0.000578	CbGpPWpGaD
Vemurafenib—BRAF—NGF signalling via TRKA from the plasma membrane—IL6—bile duct cancer	0.000466	0.000577	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—ERBB2—bile duct cancer	0.000465	0.000577	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—EGFR—bile duct cancer	0.000465	0.000576	CbGpPWpGaD
Vemurafenib—RAF1—Transmembrane transport of small molecules—GNAS—bile duct cancer	0.000465	0.000576	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—EGFR—bile duct cancer	0.000463	0.000574	CbGpPWpGaD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—GNAS—bile duct cancer	0.00046	0.000571	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—NRAS—bile duct cancer	0.00046	0.00057	CbGpPWpGaD
Vemurafenib—RAF1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—bile duct cancer	0.000459	0.000568	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—HRAS—bile duct cancer	0.000456	0.000565	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	0.000454	0.000563	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—FAR2—bile duct cancer	0.000449	0.000557	CbGpPWpGaD
Vemurafenib—RAF1—BDNF signaling pathway—HRAS—bile duct cancer	0.000448	0.000556	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—EGFR—bile duct cancer	0.000447	0.000554	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—KRAS—bile duct cancer	0.000447	0.000554	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—KRAS—bile duct cancer	0.000447	0.000554	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—KRAS—bile duct cancer	0.000447	0.000554	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	0.000445	0.000552	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—bile duct cancer	0.000445	0.000551	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—KRAS—bile duct cancer	0.000443	0.000549	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—KRAS—bile duct cancer	0.00044	0.000546	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—KRAS—bile duct cancer	0.000439	0.000544	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—KRAS—bile duct cancer	0.000437	0.000542	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—IL6—bile duct cancer	0.000436	0.000541	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—HRAS—bile duct cancer	0.000436	0.000541	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—IL6—bile duct cancer	0.000431	0.000534	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—IDH2—bile duct cancer	0.000431	0.000533	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—HRAS—bile duct cancer	0.000429	0.000532	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—ERBB2—bile duct cancer	0.000421	0.000522	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	0.000421	0.000521	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—IDH1—bile duct cancer	0.000421	0.000521	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—bile duct cancer	0.000421	0.000521	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—EGFR—bile duct cancer	0.000419	0.00052	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—IL6—bile duct cancer	0.000418	0.000517	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—TP53—bile duct cancer	0.000414	0.000514	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—RNF43—bile duct cancer	0.000413	0.000511	CbGpPWpGaD
Vemurafenib—RAF1—Insulin Signaling—HRAS—bile duct cancer	0.000412	0.000511	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MET—bile duct cancer	0.000411	0.000509	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—IL6—bile duct cancer	0.000411	0.000509	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—HRAS—bile duct cancer	0.00041	0.000508	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—HRAS—bile duct cancer	0.000408	0.000506	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—HRAS—bile duct cancer	0.000408	0.000506	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—HRAS—bile duct cancer	0.000406	0.000503	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—GNAS—bile duct cancer	0.000405	0.000502	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bile duct cancer	0.000405	0.000502	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—TGFB1—bile duct cancer	0.000404	0.000501	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—HRAS—bile duct cancer	0.000404	0.000501	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—KRAS—bile duct cancer	0.000396	0.000491	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—IL6—bile duct cancer	0.000392	0.000486	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—NOS2—bile duct cancer	0.000392	0.000486	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—IL6—bile duct cancer	0.000391	0.000484	CbGpPWpGaD
Vemurafenib—BRAF—Disease—TGFBR2—bile duct cancer	0.000389	0.000482	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—IL6—bile duct cancer	0.000389	0.000482	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—IL6—bile duct cancer	0.000387	0.000479	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—bile duct cancer	0.000383	0.000474	CbGpPWpGaD
Vemurafenib—BRAF—Neuronal System—HRAS—bile duct cancer	0.000382	0.000473	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—FAR2—bile duct cancer	0.00038	0.000471	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—HRAS—bile duct cancer	0.00038	0.000471	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—HRAS—bile duct cancer	0.00038	0.000471	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—HRAS—bile duct cancer	0.00038	0.000471	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—HRAS—bile duct cancer	0.000377	0.000467	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—HRAS—bile duct cancer	0.000374	0.000464	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	0.000374	0.000463	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—HRAS—bile duct cancer	0.000373	0.000463	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—HRAS—bile duct cancer	0.000372	0.000461	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—IDH1—bile duct cancer	0.00037	0.000459	CbGpPWpGaD
Vemurafenib—BRAF—Disease—SMAD4—bile duct cancer	0.000368	0.000457	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—IL6—bile duct cancer	0.000364	0.000451	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—IL6—bile duct cancer	0.000364	0.000451	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—IL6—bile duct cancer	0.000364	0.000451	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—MMP9—bile duct cancer	0.000361	0.000448	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—IL6—bile duct cancer	0.000361	0.000447	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—NRAS—bile duct cancer	0.00036	0.000446	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—HRAS—bile duct cancer	0.000359	0.000445	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	0.000359	0.000445	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—IL6—bile duct cancer	0.000358	0.000444	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—IL6—bile duct cancer	0.000357	0.000443	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—IL6—bile duct cancer	0.000356	0.000441	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—NRAS—bile duct cancer	0.000354	0.000439	CbGpPWpGaD
Vemurafenib—RAF1—Transmission across Chemical Synapses—HRAS—bile duct cancer	0.000345	0.000427	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MMP2—bile duct cancer	0.000343	0.000425	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—IL6—bile duct cancer	0.000342	0.000424	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—HRAS—bile duct cancer	0.000337	0.000417	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—bile duct cancer	0.000325	0.000403	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—EGFR—bile duct cancer	0.000322	0.0004	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—bile duct cancer	0.000322	0.000399	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—SLC5A5—bile duct cancer	0.000322	0.000399	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—NRAS—bile duct cancer	0.00032	0.000397	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—bile duct cancer	0.000311	0.000386	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—KRAS—bile duct cancer	0.00031	0.000384	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—GNAS—bile duct cancer	0.000308	0.000382	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—KRAS—bile duct cancer	0.000305	0.000378	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—ERBB2—bile duct cancer	0.0003	0.000372	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—FAR2—bile duct cancer	0.000294	0.000364	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—EGFR—bile duct cancer	0.000292	0.000362	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—GNAS—bile duct cancer	0.000289	0.000358	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—SLC5A5—bile duct cancer	0.000278	0.000344	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—KRAS—bile duct cancer	0.000276	0.000342	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—HGF—bile duct cancer	0.000275	0.000341	CbGpPWpGaD
Vemurafenib—BRAF—Disease—NOS2—bile duct cancer	0.000274	0.00034	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TGFBR2—bile duct cancer	0.000273	0.000338	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TGFBR2—bile duct cancer	0.000269	0.000334	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HGF—bile duct cancer	0.000268	0.000332	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TGFBR2—bile duct cancer	0.000267	0.000331	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—IDH2—bile duct cancer	0.000266	0.000329	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—ERBB2—bile duct cancer	0.000265	0.000329	CbGpPWpGaD
Vemurafenib—RAF1—Neuronal System—HRAS—bile duct cancer	0.000264	0.000327	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—HRAS—bile duct cancer	0.000263	0.000326	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—GNAS—bile duct cancer	0.000263	0.000326	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	0.00026	0.000322	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—HRAS—bile duct cancer	0.000259	0.000321	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SMAD4—bile duct cancer	0.000258	0.00032	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MMP9—bile duct cancer	0.000258	0.000319	CbGpPWpGaD
Vemurafenib—RAF1—Disease—SMAD4—bile duct cancer	0.000255	0.000316	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—ERBB2—bile duct cancer	0.000255	0.000316	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—SMAD4—bile duct cancer	0.000253	0.000313	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IL6—bile duct cancer	0.000252	0.000312	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—GNAS—bile duct cancer	0.00025	0.00031	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—IL6—bile duct cancer	0.000248	0.000307	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—SLC5A5—bile duct cancer	0.000244	0.000303	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—HRAS—bile duct cancer	0.000234	0.00029	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—NRAS—bile duct cancer	0.000229	0.000283	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—IDH1—bile duct cancer	0.000228	0.000283	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—IL6—bile duct cancer	0.000224	0.000278	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—NRAS—bile duct cancer	0.000224	0.000278	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—IDH2—bile duct cancer	0.000219	0.000272	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—TGFB1—bile duct cancer	0.000218	0.00027	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GNAS—bile duct cancer	0.000216	0.000267	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TGFB1—bile duct cancer	0.000212	0.000263	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NOS2—bile duct cancer	0.000211	0.000261	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TGFB1—bile duct cancer	0.000208	0.000258	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—EGFR—bile duct cancer	0.000208	0.000258	CbGpPWpGaD
Vemurafenib—BRAF—Disease—ERBB2—bile duct cancer	0.000206	0.000256	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—NRAS—bile duct cancer	0.000202	0.00025	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PTGS2—bile duct cancer	0.000202	0.00025	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—KRAS—bile duct cancer	0.000197	0.000244	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—NRAS—bile duct cancer	0.000194	0.00024	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—KRAS—bile duct cancer	0.000193	0.000239	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GNAS—bile duct cancer	0.00019	0.000235	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NOS2—bile duct cancer	0.00019	0.000235	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—IDH1—bile duct cancer	0.000189	0.000234	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TGFBR2—bile duct cancer	0.000189	0.000234	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NOS2—bile duct cancer	0.000188	0.000233	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—IDH2—bile duct cancer	0.000186	0.00023	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—EGFR—bile duct cancer	0.000184	0.000228	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—GNAS—bile duct cancer	0.000182	0.000225	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SMAD4—bile duct cancer	0.000179	0.000221	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—EGFR—bile duct cancer	0.000177	0.000219	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—KRAS—bile duct cancer	0.000174	0.000215	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TP53—bile duct cancer	0.000172	0.000213	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—HRAS—bile duct cancer	0.000167	0.000207	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—KRAS—bile duct cancer	0.000167	0.000207	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—HRAS—bile duct cancer	0.000164	0.000203	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—IL6—bile duct cancer	0.00016	0.000198	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—IDH1—bile duct cancer	0.00016	0.000198	CbGpPWpGaD
Vemurafenib—BRAF—Disease—NRAS—bile duct cancer	0.000157	0.000194	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ERBB2—bile duct cancer	0.000155	0.000192	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—SLC5A5—bile duct cancer	0.000151	0.000187	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—HRAS—bile duct cancer	0.000148	0.000183	CbGpPWpGaD
Vemurafenib—BRAF—Disease—TGFB1—bile duct cancer	0.000146	0.000181	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—ERBB2—bile duct cancer	0.000144	0.000179	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—IDH2—bile duct cancer	0.000143	0.000178	CbGpPWpGaD
Vemurafenib—BRAF—Disease—EGFR—bile duct cancer	0.000143	0.000177	CbGpPWpGaD
Vemurafenib—RAF1—Disease—ERBB2—bile duct cancer	0.000143	0.000177	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HRAS—bile duct cancer	0.000142	0.000176	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—ERBB2—bile duct cancer	0.000141	0.000175	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—IL6—bile duct cancer	0.000141	0.000175	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	0.000141	0.000175	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTGS2—bile duct cancer	0.00014	0.000173	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTGS2—bile duct cancer	0.000138	0.000171	CbGpPWpGaD
Vemurafenib—BRAF—Disease—KRAS—bile duct cancer	0.000135	0.000167	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—NRAS—bile duct cancer	0.000129	0.000159	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—SLC5A5—bile duct cancer	0.000124	0.000154	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MMP9—bile duct cancer	0.000124	0.000154	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—IDH1—bile duct cancer	0.000123	0.000153	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NRAS—bile duct cancer	0.000121	0.00015	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—NRAS—bile duct cancer	0.000118	0.000146	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—EGFR—bile duct cancer	0.000117	0.000145	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GNAS—bile duct cancer	0.000117	0.000145	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTGS2—bile duct cancer	0.000116	0.000144	CbGpPWpGaD
Vemurafenib—BRAF—Disease—HRAS—bile duct cancer	0.000115	0.000142	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TGFB1—bile duct cancer	0.000112	0.000139	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—KRAS—bile duct cancer	0.000111	0.000137	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NRAS—bile duct cancer	0.00011	0.000136	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IL6—bile duct cancer	0.00011	0.000136	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NRAS—bile duct cancer	0.000109	0.000135	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NRAS—bile duct cancer	0.000108	0.000133	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EGFR—bile duct cancer	0.000107	0.000133	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SLC5A5—bile duct cancer	0.000105	0.000131	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—KRAS—bile duct cancer	0.000104	0.000129	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TGFB1—bile duct cancer	0.000102	0.000127	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTGS2—bile duct cancer	0.000102	0.000126	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—KRAS—bile duct cancer	0.000101	0.000125	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TGFB1—bile duct cancer	0.000101	0.000125	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EGFR—bile duct cancer	0.0001	0.000124	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TGFB1—bile duct cancer	0.0001	0.000124	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ERBB2—bile duct cancer	9.99e-05	0.000124	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EGFR—bile duct cancer	9.89e-05	0.000123	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	9.88e-05	0.000122	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EGFR—bile duct cancer	9.8e-05	0.000121	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GNAS—bile duct cancer	9.67e-05	0.00012	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KRAS—bile duct cancer	9.46e-05	0.000117	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—HRAS—bile duct cancer	9.41e-05	0.000117	CbGpPWpGaD
Vemurafenib—RAF1—Disease—KRAS—bile duct cancer	9.34e-05	0.000116	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—KRAS—bile duct cancer	9.26e-05	0.000115	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—bile duct cancer	9.23e-05	0.000114	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6—bile duct cancer	9.01e-05	0.000112	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—HRAS—bile duct cancer	8.83e-05	0.000109	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HRAS—bile duct cancer	8.6e-05	0.000107	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MMP9—bile duct cancer	8.57e-05	0.000106	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—bile duct cancer	8.41e-05	0.000104	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6—bile duct cancer	8.23e-05	0.000102	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GNAS—bile duct cancer	8.19e-05	0.000102	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC5A5—bile duct cancer	8.14e-05	0.000101	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HRAS—bile duct cancer	8.04e-05	9.96e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HRAS—bile duct cancer	7.94e-05	9.84e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HRAS—bile duct cancer	7.87e-05	9.76e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6—bile duct cancer	7.69e-05	9.53e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NRAS—bile duct cancer	7.6e-05	9.42e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6—bile duct cancer	7.6e-05	9.42e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6—bile duct cancer	7.54e-05	9.34e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TGFB1—bile duct cancer	7.06e-05	8.75e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EGFR—bile duct cancer	6.93e-05	8.58e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KRAS—bile duct cancer	6.54e-05	8.11e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GNAS—bile duct cancer	6.32e-05	7.83e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS2—bile duct cancer	6.29e-05	7.79e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—bile duct cancer	5.82e-05	7.21e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HRAS—bile duct cancer	5.56e-05	6.89e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6—bile duct cancer	5.32e-05	6.6e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS2—bile duct cancer	5.19e-05	6.43e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS2—bile duct cancer	4.4e-05	5.45e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS2—bile duct cancer	3.4e-05	4.21e-05	CbGpPWpGaD
